2024-01-26| Partnerships

Celltrion and WuXi XDC Partner to Advance ADC Development and Manufacturing

by Sinead Huang
Share To

WuXi XDC, a global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in bioconjugates, and Celltrion, a biopharmaceutical company focused on innovative therapeutics, have entered into a strategic partnership. The Memorandum of Understanding (MOU) outlines comprehensive and integrated services for the development and manufacturing of bioconjugates, particularly antibody-drug conjugates (ADCs).

Related article: Reviewing the Market Trends in the Antibody-Drug Conjugate Development: A Focus on Roche, Sanofi, BMS, Seagen, and BioNTech

A Comprehensive Approach to Bioconjugate Development

The collaboration between WuXi XDC and Celltrion involves a delegated partnership where WuXi XDC will serve as the primary service provider for integrated projects related to bioconjugate development. This includes various stages from process development to Good Manufacturing Practice (GMP) manufacturing on a global scale. The aim is to leverage WuXi XDC’s expertise to accelerate the development of ADCs, a promising area of biopharmaceuticals.

WuXi XDC is set to play a strategic role as a service partner, supporting Celltrion’s innovative pipeline. The services encompass the entire spectrum, from process development to one-stop GMP manufacturing. This strategic collaboration aims to expedite the development of ADCs, ensuring a rapid and high-quality approach. Celltrion’s Vice President, Mr. Jong Moon Cho, expresses confidence in WuXi XDC’s advanced platform and expertise in ADC development.

Fostering Innovation for Global Healthcare

Celltrion emphasizes its commitment to fostering innovation to address unmet healthcare needs and contribute to the sustainability of healthcare systems. WuXi XDC’s CEO, Dr. Jimmy Li, highlights the excitement of collaborating with Celltrion and reaffirms their dedication to enabling clients to advance innovative therapeutics with speed and quality. The partnership reflects a shared commitment to benefit patients worldwide through cutting-edge bioconjugate solutions.

The partnership between Celltrion and WuXi XDC marks a significant step in advancing bioconjugate solutions, particularly ADCs. By combining Celltrion’s innovative pipeline with WuXi XDC’s global CRDMO capabilities, the collaboration aims to not only accelerate development but also contribute to the well-being of patients worldwide.

© All rights reserved. Collaborate with us:
Related Post
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
APAC Leading the Industry in Adoptive Cell Therapy – Trials, Economic Growth, and Pioneering Companies
Taiwan’s Biotech and Pharma Delegation: Innovations Take Center Stage at BIO 2024
Breaking Ground in Alzheimer’s with 10 Cutting-Edge Treatments Paving the Way in 2024
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
Scroll to Top